The pharmacological treatment of nystagmus

Not Applicable

Completed

• Conditions: ystagmus; Eye Diseases; Nystagmus

• Registration Number: ISRCTN58592532
• Lead Sponsor: niversity Hospitals of Leicester (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-12-05
• Last Update Posted: 4 September 2017

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

1. Patients with congenital or acquired nystagmus
2. Over the age of 16 years

Exclusion Criteria

1. Contraindication for gabapentin or memantine such as epilepsy, renal impairment, pregnancy or breast-feeding
2. For women of childbearing potential, a pregnancy test will be performed and documentation of adequate contraception during the study drug administration will be obtained
3. Patients on medication incompatible with gabapentin or memantine, such as amantadin

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in distance in Logarithm of the Minimum Angle of Resolution (LogMAR) visual acuity between memantine, gabapentin and placebo.<br><br>Each of the primary and secondary outcomes will be measured at day 0, 15, 57, 77 and 119 of each treatment arm.

Secondary Outcome Measures

Name	Time	Method
1. Change in near LogMAR visual acuity between memantine, gabapentin and placebo<br>2. Change in nystagmus intensity (expanded Nystagmus Acuity Function [NAFX]) function and reading speed will be evaluated as described above at 1.2 m for the different fixation points tested and at near for null point between memantine and gabapentin and placebo<br>3. Subjective changes in visual function by self-assessment on Visual Function 14 (VF14) questionnaire between memantine and gabapentin and placebo<br><br>Each of the primary and secondary outcomes will be measured at day 0, 15, 57, 77 and 119 of each treatment arm.